Expression of HER2 in urothelial carcinoma and its significance

被引:0
作者
Chang, Yao [1 ]
Zhao, Delong [2 ]
Wang, Zicheng [2 ,3 ]
Zhu, Kejia [2 ]
Guo, Andong [2 ]
Cao, Jishuang [4 ]
Wu, Chenrui [4 ]
Ding, Sentai [2 ,4 ]
机构
[1] Shandong First Med Univ, Cent Hosp Affiliated, Dept Urol, Jinan, Peoples R China
[2] Shandong First Med Univ, Dept Urol, Shandong Prov Hosp Affiliated, Jinan, Peoples R China
[3] Southern theater Gen Hosp, Dept Urol, Guangzhou, Peoples R China
[4] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Urol, Jinan, Peoples R China
关键词
Urothelial carcinoma; Human epidermal growth factor receptor 2; Immunohistochemistry; RECEPTOR; 2; EXPRESSION; GENE AMPLIFICATION; BLADDER-CARCINOMA; OVEREXPRESSION; HETEROGENEITY; CANCER; OCCURS;
D O I
10.1097/CU9.0000000000000249
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesWe explored the expression levels and clinical significance of human epidermal growth factor receptor 2 (HER2) in urothelial carcinoma (UC) tissues. Materials and methodsPatient data were reviewed, and 111 paraffin specimens of UC obtained from the Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, from 2020 to 2021 were collected. Immunohistochemistry was used to detect HER2 protein expression in all UC tumor tissues. The chi 2 and Fisher exact tests were used to analyze the relationship between HER2 protein expression and clinicopathological data (sex, age, histopathological diagnosis, invasiveness, histopathological grade, maximum tumor diameter, muscle invasion, regional lymph node metastasis, and clinical stage). ResultsIn this study, 92 cases (82.88%) showed HER2 protein expression, and there was a statistically significant difference in the distribution of HER2 positivity (immunohistochemistry 2+ and 3+) according to the pathological grades of UC (p = 0.021). Human epidermal growth factor receptor 2 positivity was not associated with sex, age, histopathological diagnosis, invasiveness, maximum tumor diameter, muscle invasion, regional lymph node metastasis, or clinical stage (all p < 0.05). ConclusionsHuman epidermal growth factor receptor 2 protein is highly expressed in UC, and its expression may be closely related to the high pathological grade of UC.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 36 条
[1]  
[Anonymous], 2016, Cancer Discov, V6, pOF13, DOI [10.1158/2159-8290.cd-rw2016-069, 10.1158/2159-8290.CD-RW2016-069]
[2]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[3]   Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management [J].
Bellmunt, Joaquim ;
Valderrama, Begona P. ;
Puente, Javier ;
Grande, Enrique ;
Victoria Bolos, M. ;
Lainez, Nuria ;
Vazquez, Sergio ;
Maroto, Pablo ;
Angel Climent, Miguel ;
Garcia del Muro, Xavier ;
Angel Arranz, Jose ;
Duran, Ignacio .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
[4]   HER2 as a target in invasive urothelial carcinoma [J].
Bellmunt, Joaquim ;
Werner, Lillian ;
Bamias, Aristotle ;
Fay, Andre P. ;
Park, Rachel S. ;
Riester, Markus ;
Selvarajah, Shamini ;
Barletta, Justine A. ;
Berman, David M. ;
de Muga, Silvia ;
Salido, Marta ;
Gallardo, Enrique ;
Rojo, Federico ;
Guancial, Elizabeth A. ;
Bambury, Richard ;
Mullane, Stephanie A. ;
Choueiri, Toni K. ;
Loda, Massimo ;
Stack, Edward ;
Rosenberg, Jonathan .
CANCER MEDICINE, 2015, 4 (06) :844-852
[5]   Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder [J].
Bolenz, Christian ;
Shariat, Shahrokh F. ;
Karakiewicz, Pierre I. ;
Ashfaq, Raheela ;
Ho, Richard ;
Sagalowsky, Arthur I. ;
Lotan, Yair .
BJU INTERNATIONAL, 2010, 106 (08) :1216-1222
[6]   HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization [J].
Ching, Christina B. ;
Amin, Mahul B. ;
Tubbs, Raymond R. ;
Elson, Paul ;
Platt, Eric ;
Dreicer, Robert ;
Fergany, Amr ;
Hansel, Donna E. .
MODERN PATHOLOGY, 2011, 24 (08) :1111-1119
[7]   Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases [J].
Chivukula, Mamatha ;
Bhargava, Rohit ;
Brufsky, Adam ;
Surti, Urvashi ;
Dabbs, David J. .
MODERN PATHOLOGY, 2008, 21 (04) :363-368
[8]   Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach? [J].
Cimpean, Anca Maria ;
Tarlui, Valeria ;
Cumpanas, Alin Adrian ;
Bolintineanu, Sorin ;
Cumpanas, Andrei ;
Raica, Marius .
ANTICANCER RESEARCH, 2017, 37 (09) :4935-4942
[9]   Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer [J].
Cottu, P. H. ;
Asselah, J. ;
Lae, M. ;
Pierga, J. -Y. ;
Dieras, V. ;
Mignot, L. ;
Sigal-Zafrani, B. ;
Vincent-Salomon, A. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :596-597
[10]   An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next [J].
D'Angelo, Alberto ;
Chapman, Robert ;
Sirico, Marianna ;
Sobhani, Navid ;
Catalano, Martina ;
Mini, Enrico ;
Roviello, Giandomenico .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (03) :191-205